HWHe-Ling Wen

He-Ling Wen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


He-Ling Wen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Jike Jiang

    College of Basic Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, People’s Republic of China

    1 shared publication
  • Ju Li

    College of Basic Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, People’s Republic of China

    1 shared publication
  • Kan Yang

    Department of Cardiology, The Third Xiangya Hospital of Central South University 138 Tongzipo Road, Changsha 410013, Hunan, China

    1 shared publication
  • Rui Zhang

    Department of Cardiovascular and Thoracic Surgery, The Seventh People’s Hospital of Chengdu, No. 1 Twelfth Middle Street, Chengdu, Sichuan, 610041, P.R.China

    1 shared publication
  • Ruifen Sun

    Center for Scientific Research, Yunnan University of Chinese Traditional Medicine, Kunming, Yunnan, People’s Republic of China

    1 shared publication
  • Shaoqing Shi

    Department of Clinical Research Center, First Affiliated Hospital of Kunming Medical University, Kunming, China

    1 shared publication

Latest Publications

  • Open Access

    ERK Activation-Mediated Autophagy Induction Resists Licochalcone A-Induced Anticancer Activities in Lung Cancer Cells in vitro

    by Wei Luo, Ruifen Sun, Xin Chen, Ju Li, Jike Jiang, Yuxiao He, Shaoqing Shi, Heling Wen

    Introduction: The incidence and mortality rates of lung cancer rank top in the different types of cancers in China. Licochalcone A (LA) is a flavonoid extracted from the roots of licorice with antitumor effects in various cancers in vitro and in vivo. However, the role of LA in non-small cell lung cancer (NSCLC) remains largely unclear. Methods: The cell viability was measured by MTT assay, Edu staining and colony formation assay. Apoptosis was investigated using Annexin V/PI double-stained assays with flow cytometry. Real-time quantitative RT-PCR was carried out to investigate the expression of mRNA of related proteins. Western blotting was used to investigate the expression of related proteins. Results: The results show that LA inhibits the proliferation of NSCLC cells in a dose-dependent manner and induces apoptotic cell death. Moreover, LA significantly suppresses the expression of c-IAP1, c-IAP2, XIAP, Survivin, c-FLIPL and RIP1 without influencing the level of mRNA. Cycloheximide chase assay demonstrates that LA greatly decreases the stability of Survivin, XIAP and RIP1. Mechanistic studies indicate that LA induces cytoprotective autophagy since block of autophagy with CQ greatly enhances LA-induced anticancer activities. Furthermore, LA rapidly induces ERK and p38 activation in a time-dependent manner in both A549 and H460 cells, but suppresses the activities of c-Jun N-terminal kinase (JNK); suppression of ERK not p38 with inhibitor attenuates LA-induced autophagy, while it remarkably enhances LA-induced cytotoxicity in lung cancer cells and further promotes the degradation of apoptosis-related proteins. Discussion: The results of this study provide novel insights on the role of apoptosis-related proteins and the MAPKs pathway in the anticancer activities of LA.


  • Open Access

    Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy

    by He-Ling Wen, Zhong-Shu Liang, Rui Zhang, Kan Yang

    Aims: Given the importance of inflammation in the onset and progression of diabetic cardiomyopathy, we investigated the potential protective effects of triptolide, an anti-inflammatory agent, in streptozotocin-induced diabetic rat model and in H9c2 rat cardiac cells exposed to high glucose. Methods and results: Diabetic rats were treated with triptolide (100, 200, or 400 μg/kg/day respectively) for 6 weeks. At the end of this study, after cardiac function measurements were performed, rats were sacrificed and their hearts were harvested for further histologic and molecular biologic analysis. Enhanced activity and expression of nuclear factor-kappaB (NF-κB) p65 in diabetic hearts were associated with increased inflammatory response, as demonstrated by increased pro-inflammatory cytokines, cell adhesion molecules and invading inflammatory cells, as well as increased fibrosis, in line with impaired left ventricular function. Triptolide attenuated these morpho-functional alterations. Furthermore, triptolide (20 ng/ml) also attenuated high glucose-induced inflammation in H9c2 rat cardiac cells. Conclusion: Our data demonstrate that anti-inflammatory effects of triptolide involving the NF-κB signaling pathway can improve left ventricular function under diabetic conditions, suggesting triptolide treatment might be beneficial in diabetic cardiomyopathy.